VettaFi Weight Loss Drug & Treatment Index

An index of global companies expected to economically benefit from GLP-1 drug development, approval, or market adoption. This includes companies who are manufacturers in the GLP-1 pharmaceuticals business or are GLP-1 enablers. The index allocates 70% of its weight to a Principal Manufacturers segment and 30% to an Enablers segment.

As July 17, 2024 Index Level 3-Month 6-Month 1-Year YTD
Price Return 1,597.8 10.6% 23.6% 37.9% 25.8%
Total Return 1,681.7 10.9% 24.8% 40.2% 27.0%
Net Total Return 1,662.0 10.8% 24.5% 39.7% 26.7%
Index Level 1,597.8
3-Month 10.6%
6-Month 23.6%
1-Year 37.9%
YTD 25.8%
Index Level 1,681.7
3-Month 10.9%
6-Month 24.8%
1-Year 40.2%
YTD 27.0%
Index Level 1,662.0
3-Month 10.8%
6-Month 24.5%
1-Year 39.7%
YTD 26.7%

As of July 17, 2024

Characteristics

Index Symbol (Price Return) THINR
Index Symbol (Total Return) THINRT
Index Symbol (Net Total Return) THINRN
Number of Constituents 27
Market Capitalization $2.88 Trillion
Adjusted Market Capitalization $2.75 Trillion
Rebalancings Quarterly
Dividend Yield 1.42%

Composition

Top Index Constituents
As of July 18, 2024

Interested in Market Data packages?

VettaFi's indexes are widely used by financial firms, industry stakeholders and professionals to support a variety of business functions. We offers a range of end-of-day and historical index data subscriptions.

Contact Us